Daniel Saltzstein, MD

Articles by Daniel Saltzstein, MD

Integrating Genomic Testing into mCSPC Management

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 22nd 2025

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

Patient Counseling for Doublet versus triplet Therapy in mCSPC

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 22nd 2025

Healthcare professionals discuss the importance of patient counseling on treatment options, emphasizing the balance between efficacy and quality of life.

Identifying the Ideal Patient for Doublet versus triplet in mCSPC

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 15th 2025

Identifying the Ideal Patient for Doublet versus triplet in mCSPC

Evaluating Long-Term ARPI Clinical Trial Data in mCSPC

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 15th 2025

Explore the latest long-term data on abiraterone and enzalutamide, revealing survival benefits and safety insights for prostate cancer treatments.

Mechanistic Differences in ARPIs and Long-Term Clinical Outcomes in mCSPC

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 8th 2025

Explore the evolving landscape of prostate cancer treatments, focusing on efficacy, tolerability, and the nuances of various therapies.

Addressing Unmet Needs in mCSPC Care

ByDavid Morris, MD, FACS,Daniel Saltzstein, MD,Stephen J. Freedland, MD,Tim A. Richardson, MD

December 8th 2025

Experts discuss the future of metastatic cancer treatment, focusing on risk stratification, personalized therapies, and the balance between intensification and de-escalation.